ID: ALA540368

Max Phase: Preclinical

Molecular Formula: C23H27ClN4O4S

Molecular Weight: 454.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NCS(=O)(=O)c2ccccc2)c(O)c1CC(=O)NCc1ccc(N)nc1C.Cl

Standard InChI:  InChI=1S/C23H26N4O4S.ClH/c1-15-8-10-20(26-14-32(30,31)18-6-4-3-5-7-18)23(29)19(15)12-22(28)25-13-17-9-11-21(24)27-16(17)2;/h3-11,26,29H,12-14H2,1-2H3,(H2,24,27)(H,25,28);1H

Standard InChI Key:  LIQWGMJDFIEQEU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 454.55

Molecular Weight (Monoisotopic): 454.1675

AlogP: 2.69

#Rotatable Bonds: 8

Polar Surface Area: 134.41

Molecular Species: NEUTRAL

HBA: 7

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.06

CX Basic pKa: 7.32

CX LogP: 1.86

CX LogD: 1.61

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.38

Np Likeness Score: -1.03

References

1. Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y..  (2006)  Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.,  16  (4): [PMID:16290930] [10.1016/j.bmcl.2005.10.082]

Source

Source(1):

• Scientific Literature